| Vitality Chiropractic Lifestyle Center | |
|
214 E Staples St, Arthur, NE 69121-8410 | |
| (308) 284-0838 | |
| (308) 284-0848 |
| Full Name | Vitality Chiropractic Lifestyle Center |
|---|---|
| Type | Facility |
| Speciality | Chiropractor |
| Location | 214 E Staples St, Arthur, Nebraska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255721189 | NPI | - | NPPES |
| 10026132200 | Medicaid | NE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 1567 (Nebraska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Vitality Chiropractic Lifestyle Center Po Box 96, Ogallala, NE 69153-0096 Ph: (308) 284-0838 | Vitality Chiropractic Lifestyle Center 214 E Staples St, Arthur, NE 69121-8410 Ph: (308) 284-0838 |
News Archive
Twitter may be an effective, untapped resource to stimulate interest in cancer clinical trials and boost enrollment, physicians at the Abramson Cancer Center of the University of Pennsylvania suggest in a new research letter in JAMA Oncology. Analyzing thousands of lung cancer tweets on the social media site revealed that a surprisingly large number were about clinical trials, particularly ones on immunotherapy, although none were used for recruitment.
Most people recognize that there is a relationship between cholesterol levels and risk of heart disease. But new research from Copenhagen University Hospital and University of Copenhagen shows that a certain kind of cholesterol might affect our health differently, that is, through a role in the immune system.
At an event on Thursday to commemorate the 50th anniversary of the Foreign Assistance Act of 1961, co-hosted by the American Enterprise Institute (AEI) and the Brookings Institute, House Foreign Affairs Committee ranking member Rep. Howard Berman unveiled a discussion draft of the Global Partnerships Act of 2011, aimed at "reshaping foreign assistance, making it more relevant 'by incorporating the best practices and lessons learned over the last half century,'" he said, the Malaria Policy Center's "Malaria Watch" blog reports.
DURECT Corporation today announced that it has signed a development and license agreement with Orient Pharma Co., Ltd., a diversified multinational pharmaceutical, healthcare and consumer products company with headquarters in Taiwan, under which DURECT has granted to Orient Pharma development and commercialization rights in selected Asian and South Pacific countries to a drug candidate based on DURECT's ORADUR(R) Technology and one specified active pharmaceutical ingredient for the treatment of attention deficit hyperactivity disorder (ADHD).
› Verified 1 days ago